This content is from: Portfolio MIT’s Andrew Lo Touts Megafund to Tackle Cancer, Rare Diseases The Massachusetts Institute of Technology finance professor has run simulations showing that such funds could post healthy returns. By Kaitlin Ugolik October 26, 2015
This content is from: Premium Perceptive Gets a Big Boost From Pfizer’s Array Deal The healthcare and biotech specialist enjoyed hefty gains in many of its top holdings on Monday. By Stephen Taub June 18, 2019
This content is from: Premium Joseph Edelman’s Perceptive Posts Another Gargantuan Gain Several of the firm’s biotech holdings tripled in value in 2017, leading to a third 40-plus percent return in five years. By Stephen Taub January 23, 2018
This content is from: Premium Howard Lutnick Backs the Worldwide Orphans Foundation The Cantor Fitzgerald founder on the highly personal reasons behind why he supports Worldwide Orphans. November 08, 2012
This content is from: Premium Perceptive Advisors Suffers Setback in 2018 The health care fund is still one of the top performers over the past decade in spite of a loss last year. By Stephen Taub January 28, 2019
This content is from: Research 2015 All-America Research Team: Biotechnology/Large-Cap, No. 3: Geoffrey Meacham Geoffrey Meacham left J.P. Morgan and has since December been leading Barclays’s coverage of major biotechnology and pharmaceuticals names. By Tyler Davies October 07, 2015
